Cargando…

Correction: Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138016/ http://dx.doi.org/10.1371/journal.pone.0106174

Ejemplares similares

Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology
por: Burgos, Kasandra, et al.
Publicado: (2014)

Cerebrospinal Fluid and Plasma Small Extracellular Vesicles and miRNAs as Biomarkers for Prion Diseases
por: López-Pérez, Óscar, et al.
Publicado: (2021)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease
por: dos Santos, Marcia Cristina T., et al.
Publicado: (2018)

Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease
por: Lobanova, Evgeniia, et al.
Publicado: (2021)

Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology
por: Hu, Hao, et al.
Publicado: (2020)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson’s Disease Cases Lacking Alzheimer’s Disease Pathology
por: Maarouf, Chera L., et al.
Publicado: (2013)

Corrigendum to: Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease
Publicado: (2021)

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
por: Gui, YaXing, et al.
Publicado: (2015)

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study
por: Sørensen, Sofie Sølvsten, et al.
Publicado: (2016)

Author Correction: A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease
por: Xiang, Chunchen, et al.
Publicado: (2023)

Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
por: De Kort, Anna M., et al.
Publicado: (2021)

Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Correction to: miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson’s disease
por: Liu, Xiaoting, et al.
Publicado: (2019)

Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by Next-Generation Sequencing
por: Buschmann, Dominik, et al.
Publicado: (2019)

Extracellular Vesicles Loaded miRNAs as Potential Modulators Shared Between Glioblastoma, and Parkinson’s and Alzheimer’s Diseases
por: Thomas, Laura, et al.
Publicado: (2020)

Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
por: Ouanes, Sami, et al.
Publicado: (2022)

Metallomic Biomarkers in Cerebrospinal fluid and Serum in patients with Parkinson’s disease in Indian population
por: Sanyal, Jaya, et al.
Publicado: (2016)

Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson’s disease
por: Hasíková, Lenka, et al.
Publicado: (2023)

A Panel of Exosome-Derived miRNAs of Cerebrospinal Fluid for the Diagnosis of Moyamoya Disease
por: Wang, Gang, et al.
Publicado: (2020)

Correction: Cerebrospinal Fluid Melanin-Concentrating Hormone (MCH) and Hypocretin-1 (HCRT-1, Orexin-A) in Alzheimer’s Disease
por: Schmidt, Frank M., et al.
Publicado: (2013)

Metabolomic investigations in cerebrospinal fluid of Parkinson's disease
por: Willkommen, Desiree, et al.
Publicado: (2018)

Importance of extracellular vesicle secretion at the blood–cerebrospinal fluid interface in the pathogenesis of Alzheimer’s disease
por: Vandendriessche, Charysse, et al.
Publicado: (2021)

Extracellular Matrix Changes in Subcellular Brain Fractions and Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Höhn, Lukas, et al.
Publicado: (2023)

Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer’s disease
por: ZHU, YAN, et al.
Publicado: (2015)

The Cerebrospinal Fluid Profile of Cholesterol Metabolites in Parkinson’s Disease and Their Association With Disease State and Clinical Features
por: Griffiths, William J., et al.
Publicado: (2021)

Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease
por: Keighron, Cameron Noah, et al.
Publicado: (2023)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer’s disease pathology and cognitive function
por: Zhao, Li-Jing, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Profiling Inflammatory Extracellular Vesicles in Plasma and Cerebrospinal Fluid: An Optimized Diagnostic Model for Parkinson’s Disease
por: Vacchi, Elena, et al.
Publicado: (2021)

Altered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease
por: Visconte, Caterina, et al.
Publicado: (2023)

Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
por: Kim, Dana, et al.
Publicado: (2016)

Predictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
por: Hwangbo, Nathan, et al.
Publicado: (2022)

Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression
por: Christine, Chadwick W., et al.
Publicado: (2020)

Identification of Candidate Biomarkers of Alzheimer’s Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics
por: Liu, Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ck2ioauhsq3cdopa0gi9cs0n3k